Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The interaction between RUNX2 and core binding factor beta (CBFβ) as a potential therapeutic target in canine osteosarcoma.

Alegre F, Ormonde AR, Godinez DR, Illendula A, Bushweller JH, Wittenburg LA.

Vet Comp Oncol. 2019 Aug 5. doi: 10.1111/vco.12526. [Epub ahead of print]

PMID:
31381810
2.

Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.

Fultang N, Illendula A, Chen B, Wu C, Jonnalagadda S, Baird N, Klase Z, Peethambaran B.

PLoS One. 2019 May 31;14(5):e0217789. doi: 10.1371/journal.pone.0217789. eCollection 2019.

3.

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN.

Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25.

PMID:
31023702
4.

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.

Zhou N, Gutierrez-Uzquiza A, Zheng XY, Chang R, Vogl DT, Garfall AL, Bernabei L, Saraf A, Florens L, Washburn MP, Illendula A, Bushweller JH, Busino L.

Leukemia. 2019 Aug;33(8):2006-2021. doi: 10.1038/s41375-019-0403-2. Epub 2019 Feb 13.

5.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Aug 23;174(5):1325. doi: 10.1016/j.cell.2018.08.014. No abstract available.

PMID:
30142347
6.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Jun 28;174(1):172-186.e21. doi: 10.1016/j.cell.2018.05.048. Erratum in: Cell. 2018 Aug 23;174(5):1325.

7.

Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Carlton AL, Illendula A, Gao Y, Llaneza DC, Boulton A, Shah A, Rajewski RA, Landen CN, Wotton D, Bushweller JH.

Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.

8.

A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells.

Oo ZM, Illendula A, Grembecka J, Schmidt C, Zhou Y, Esain V, Kwan W, Frost I, North TE, Rajewski RA, Speck NA, Bushweller JH.

Leuk Lymphoma. 2018 Sep;59(9):2188-2200. doi: 10.1080/10428194.2017.1410882. Epub 2017 Dec 18.

9.

Corrigendum to: "Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers" [EBioMedicine 8 (2016) 117-131].

Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH.

EBioMedicine. 2017 Nov;25:188. doi: 10.1016/j.ebiom.2017.10.029. Epub 2017 Oct 31. No abstract available.

10.

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia.

Choi A, Illendula A, Pulikkan JA, Roderick JE, Tesell J, Yu J, Hermance N, Zhu LJ, Castilla LH, Bushweller JH, Kelliher MA.

Blood. 2017 Oct 12;130(15):1722-1733. doi: 10.1182/blood-2017-03-775536. Epub 2017 Aug 8.

11.

Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers.

Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH.

EBioMedicine. 2016 Jun;8:117-131. doi: 10.1016/j.ebiom.2016.04.032. Epub 2016 Apr 29. Erratum in: EBioMedicine. 2017 Nov;25:188.

12.

Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.

Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, Zhou Y, Boulton A, Kuntimaddi A, Gao Y, Rajewski RA, Guzman ML, Castilla LH, Bushweller JH.

Science. 2015 Feb 13;347(6223):779-84. doi: 10.1126/science.aaa0314.

13.

Determination of antimalarial compound, ARB-89 (7β-hydroxy-artemisinin carbamate) in rat serum by UPLC/MS/MS and its application in pharmacokinetics.

Pabbisetty D, Illendula A, Muraleedharan KM, Chittiboyina AG, Williamson JS, Avery MA, Avery BA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 15;889-890:123-9. doi: 10.1016/j.jchromb.2012.02.007. Epub 2012 Feb 13.

PMID:
22365535

Supplemental Content

Loading ...
Support Center